ABSTRACT
Judging from the metabolites found in the urine, 1-methyl-androst-1-en-17β-ol-3-one (methenolone) and testosterone are metabolized in a different manner. For further clarification, other derivatives of testosterone with modifications in Ring A were investigated with regard to the oxidation of the 17-hydroxyl group. The production of urinary 17-ketosteroids decreased in the following sequence: testosterone; 1α-methyltestosterone and androstan-17β-ol-3-one; 1β-methyl-androstan-17β-ol-3-one; 2α-methyl-androstan-17β-ol-3-one and androst-1-en-17β-ol-3-one; 1α-methyl-androstan-17β-ol-3-one; 1-methyl-androsta-1,4-dien-17β-ol-3-one; 1,17α-dimethyl-androst-1-en-17β-ol-3-one and 1 -methyl-androst-1 -en-17β-ol-3-one (methenolone).
The difference in metabolic degradation is also demonstrated in the fractionation of the urinary ketones. While after the administration of testosterone practically only hydrogenated 17-ketones are observed in the urine, the unchanged compound is still traceable in remarkable quantities after the administration of methenolone, along with minor quantities of the corresponding diketone. Testosterone-metabolites here are absent, whereas they represent the major substances present after the administration of androst-1-en-17β-ol-3-on. Following the administration of 1α-methyltestosterone only hydrogenated 17-ketones are detected which are still partly methylated.
The 1-methyl-group and the Δ 1-double-bond seem to be responsible for the inhibition of the oxidation of methenolone in the 17-position. In addition, the hydrogenation of the double-bond and the reduction of the 3-keto-group are inhibited, obviously on account of the same structural peculiarities. The demethylation of methenolone is also inhibited.
Any change in the steroid ring system forms a new substrate, thus producing new conditions for the enzymatic attack in the metabolic degradation.